HER2-positive breast cancer
HER2-positive breast cancer
复制标题
her2阳性乳腺癌
DOI：
10.1016/s0140-6736(16)32417-5
复制
发表时间：
2017-06-17
期刊：
影响因子：
168.9
通讯作者：
Gianni, Luca
中科院分区：
文献类型：
--
作者：
Loibl, Sibylle;Gianni, Luca
her2阳性乳腺癌的抗her2治疗已经改变了这种疾病的自然生物学特性。本系列文章回顾了迄今为止在转移性和早期her2阳性乳腺癌治疗方面的主要成就。新辅助治疗her2阳性早期乳腺癌的成功尤其得到认可，因为在新辅助研究中，帕妥珠单抗和曲妥珠单抗获得病理完全缓解的患者比例高于单曲妥珠单抗，因此帕妥珠单抗获得批准。在确认性辅助试验完成招募后，帕妥珠单抗联合曲妥珠单抗的无事件生存率在数字上优于单抗曲妥珠单抗。转移性her2阳性乳腺癌妇女的生存率几乎为5年，75%的患者达到病理完全缓解，过去十年的新疗法明显改善了her2阳性乳腺癌的预后。然而，尽管取得了这些成就，her2阳性乳腺癌导致的死亡率仍然很高，这要求对新疗法和联合疗法进行持续深入的临床研究。
Anti-HER2 treatment for HER2-positive breast cancer has changed the natural biology of this disease. This Series article reviews the main achievements so far in the treatment of both metastatic and early HER2-positive breast cancer. The success of neoadjuvant therapy in HER2-positive early breast cancer is especially acknowledged, as pertuzumab has been approved on the basis of a higher proportion of patients achieving a pathological complete response with pertuzumab and trastuzumab than with trastuzumab alone in a neoadjuvant study. Event-free survival after the confirmatory adjuvant trial completed recruitment was numerically better with pertuzumab plus trastuzumab than with trastuzumab alone. With survival rates of almost 5 years in women with metastatic HER2-positive breast cancer and 75% of patients achieving a pathological complete response, new treatments in the past decade have clearly improved the prognosis of HER2-positive breast cancer. Despite these achievements, however, the persisting high toll of deaths resulting from HER2-positive breast cancer calls for continued, intensive clinical research of newer therapies and combinations.